ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,948.20
0.00%
S&P ASX All Technology
3,629.80
0.00%
Brent Oil
70.235
0.00%
US Dollar vs AUD
1.59084
0.00%
Bitcoin
83,087.45
-3.54%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Aligos Therapeutics Inc (ALGS) Share Price

Aligos Therapeutics Inc

Aligos Therapeutics Inc (ALGS)

NASDAQ
12.94
-0.54
(-4.01%)
Closed 10 March 7:00AM
Delayed by 15 minutes
13.05
0.11
(0.85%)
After Hours: 11:45AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
13.05
Bid
12.23
Offer
23.66
Volume
260,431
11.911 Day's Range 13.41
6.76 52 Week Range 46.80
Market Cap
46.822M
Previous Close
13.48
Open
13.21
Last Trade
25
@
13.34
Last Trade Time
Financial Volume
US$ 3,290,733
VWAP
12.6357
Average Volume (3m)
320,403
Shares Outstanding
3,587,892
Dividend Yield
-
PE Ratio
-0.53
Earnings Per Share (EPS)
-24.44
Revenue
15.53M
Net Profit
-87.68M

About Aligos Therapeutics Inc

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.aligos.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Aligos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALGS. The last closing price for Aligos Therapeutics was US$13.48. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 6.76 to US$ 46.80.

Aligos Therapeutics currently has 3,587,892 shares in issue. The market capitalisation of Aligos Therapeutics is US$48.36 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.53.

Ask ADVFN Intelligence (AI)

ALGS Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 March 2025
ALGS (-4.01%)

Form D - Notice of Exempt Offering of Securities
Edgar (US Regulatory)
01 March 2025
ALGS (-4.01%)

Form 8-K - Current report
Edgar (US Regulatory)
13 February 2025
ALGS (-4.01%)

Form 8-K - Current report
Edgar (US Regulatory)
04 February 2025
ALGS (-4.01%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
19 November 2024
ALGS (-4.01%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.1328-19.358825419616.182817.3912.760116290314.67182079CS
4-14.95-53.39285714292829.5412.760123143219.91111241CS
12-22.024-62.792952044235.07446.812.760132040331.34307232CS
26-0.1-0.76045627376413.1546.86.7631617523.98414705CS
52-12.2-48.316831683225.2546.86.7633663419.53122791CS
156-43.2-76.856.2574.756.7626555326.29132531CS
260-355.45-96.4586160109368.5937.74756.76255917118.19696409CS

ALGS - Frequently Asked Questions (FAQ)

What is the current Aligos Therapeutics share price?
The current share price of Aligos Therapeutics is US$ 13.05
How many Aligos Therapeutics shares are in issue?
Aligos Therapeutics has 3,587,892 shares in issue
What is the market cap of Aligos Therapeutics?
The market capitalisation of Aligos Therapeutics is USD 48.36M
What is the 1 year trading range for Aligos Therapeutics share price?
Aligos Therapeutics has traded in the range of US$ 6.76 to US$ 46.80 during the past year
What is the PE ratio of Aligos Therapeutics?
The price to earnings ratio of Aligos Therapeutics is -0.53
What is the cash to sales ratio of Aligos Therapeutics?
The cash to sales ratio of Aligos Therapeutics is 2.99
What is the reporting currency for Aligos Therapeutics?
Aligos Therapeutics reports financial results in USD
What is the latest annual turnover for Aligos Therapeutics?
The latest annual turnover of Aligos Therapeutics is USD 15.53M
What is the latest annual profit for Aligos Therapeutics?
The latest annual profit of Aligos Therapeutics is USD -87.68M
What is the registered address of Aligos Therapeutics?
The registered address for Aligos Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Aligos Therapeutics website address?
The website address for Aligos Therapeutics is www.aligos.com
Which industry sector does Aligos Therapeutics operate in?
Aligos Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAPSCapstone Holding Corp
US$ 3.50
(1,300.00%)
36.33k
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.13M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.77M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
570.43k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.54M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.13M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
332.1k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
333.91M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
140.23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
140.05M

ALGS Discussion

View Posts
PonkenPlonken PonkenPlonken 2 months ago
anyone understand this move?
I thought they gave up on fundamentals and wanted to cater to the low float crowd hence the 1/25
founder sold similar company prior.... maybe repeat history
👍️0
tw0122 tw0122 4 months ago
Time to cash in some free shares .$14,62 + 50%
👍️0
DewDiligence DewDiligence 6 months ago
There were no recent insider stock purchases; rather, the three insider transactions dated 9/6/24 were company grants of stock options to the CEO, CFO, and CCO (read the footnotes):

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000465/xslF345X05/form4.xml (CEO)

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000466/xslF345X05/form4.xml (CFO)

https://www.sec.gov/Archives/edgar/data/1799448/000161071724000464/xslF345X05/form4.xml (CSO)
👍️0
tw0122 tw0122 6 months ago
Insider buy at $11.74 and it finally runs
👍️0
Monksdream Monksdream 8 months ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 8 months ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 9 months ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 10 months ago
ALGS 1Q24 results:

https://www.globenewswire.com/news-release/2024/05/07/2877224/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-First-Quarter-2024-Financial-Results.html

Cash at 3/31/24 was $112.7M, down from $135.7M at 12/31/23.

No details on when a phase-2 COVID trial, with support from NIH, will start. The PR merely says, “phase-2 enabling activities…are underway.”

No CC.
👍️0
BurgerKing82 BurgerKing82 1 year ago
Is March 7 a significant catalyst to get in by?
👍️0
TheFinalCD TheFinalCD 1 year ago
$ALGS PHASE 1 NEWS https://finviz.com/quote.ashx?t=ALGS&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/ALGS?a=dbb88c
👍️0
DewDiligence DewDiligence 1 year ago
ALGS 3Q23 results:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500015.html

No CC.
👍️0
DewDiligence DewDiligence 1 year ago
ALGS -15% on warrant-laden $92M financing:

https://www.globenewswire.com/news-release/2023/10/23/2764690/0/en/Aligos-Therapeutics-Announces-92-Million-Private-Placement-Financing.html
👍️0
DewDiligence DewDiligence 1 year ago
ALGS receives $8.5M NIAID grant for clinical development of ALG-097558:

https://finance.yahoo.com/news/aligos-therapeutics-announces-award-8-113000446.html

$8.5M won’t go very far, but I suppose that every little bit helps. ALGS is expected to report data from the phase-1 trial of ALG-097558 in 1H24.
👍️0
Monksdream Monksdream 1 year ago
ALGS new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 1 year ago
ALG-055009 phase-2a in NASH expected_to_start 1Q24:

https://finance.yahoo.com/news/aligos-therapeutics-announces-ind-clearance-113000003.html

ALG-055009 is a thyroid hormone receptor beta agonist.
👍️0
Monksdream Monksdream 1 year ago
ALGS new 52 week low
👍️0
DewDiligence DewDiligence 2 years ago
ALGS, JNJ reach agreement in principle to settle pending litigation:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001799448/000119312523200617/d538755d8k.htm

The terms will presumably be disclosed when the settlement in finalized.
👍️0
DewDiligence DewDiligence 2 years ago
The relatively low cash burn in 2Q23 was due to ALGS’ slashing R&D expenses by more than half relative to 2Q22 ($17M in 2Q23 vs 2Q22 $35M).
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 2Q23 results—6/30/23 cash=$91M—(down $15M from 3/31/23):

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500975.html

Data from the phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, are expected in 1H24. The trial, which is being conducted in the UK, is currently in the SAD phase.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS HBV data at EASL:

https://www.globenewswire.com/news-release/2023/06/21/2692513/0/en/Aligos-Therapeutics-Presents-Data-from-its-Liver-Disease-Programs-at-the-European-Association-for-the-Study-of-the-Liver-EASL-Congress-2023.html
👍️0
DewDiligence DewDiligence 2 years ago
ALGS +51%/AH on collaboration with Chinese company:

https://finance.yahoo.com/news/aligos-therapeutics-announces-research-collaboration-210500298.html Under the terms of the agreement, Aligos and Amoytop* will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales. Before the AH pop, ALGS’ enterprise value was deeply negative; after the AH pop, the EV is still negative but less so.

The up-front cash amount is presumably tiny since it wasn’t disclosed.

*Xiamen Amoytop Biotech Company Ltd.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 1Q23 results—3/31/22 cash=$104M, down from $126M at 12/31/22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500905.html

ALGS expects to start a phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, in the UK in mid 2023.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 4Q22 results—12/31/22 cash=$126M—4Q22 cash_burn=$16M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-210500130.html

ALGS’ COVID protease inhibitor, ALG-097558, is expected to start phase-1 in 2Q23.

No CC.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS “de-prioritizes” HBV program—reduces workforce 10%:

https://finance.yahoo.com/news/aligos-therapeutics-announces-strategic-reprioritization-210500405.html Aligos Therapeutics…today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck…

Additionally, the Company plans to complete the <=48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

This portfolio reprioritization is being accompanied by a reduction of the Company’s current workforce of approximately 10%...

…As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024. In other words, the HBV program is getting the axe. After completing the early-stage HBV trials in progress, ALGS will offload these assets (if anyone wants them) or simply shut down the program.

The stock is flattish in the AH session.
👍️0
Laster Laster 2 years ago
Might hit $3 today.
Easily moving to $5.
Discussed this on HEPA board at under $1 in December.
Wow.
Yippee.
👍️0
Laster Laster 2 years ago
Beautiful. Will pass $2 today.
Best NASH play out there.
Good luck.
👍️0
Laster Laster 2 years ago
It’s running.
Amazing NASH stock.
$1.20.
$3 in February.
👍️0
DewDiligence DewDiligence 2 years ago
ALGS provides 2023 roadmap:

https://www.globenewswire.com/news-release/2023/01/05/2583624/0/en/Aligos-Therapeutics-on-Track-to-Complete-Phase-2-Enabling-Activities-in-2023-for-its-Clinically-Validated-THR-%C3%9F-Drug-Candidate-for-NASH-ALG-055009.html
👍️0
DewDiligence DewDiligence 2 years ago
ALGS 3Q22 results—9/30/22 cash=$142M—3Q22 cash_burn=$17M:

https://www.globenewswire.com/news-release/2022/11/02/2547039/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Third-Quarter-2022-Financial-Results.html

ALGS’ COVID protease inhibitor, ALG-097558 is expected to start phase-1 in 2Q23.

No CC.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS 2Q22 results—6/30/22 cash=$159.3M—(down from $183M @3/31/22):

https://www.globenewswire.com/news-release/2022/08/04/2492772/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2022-Financial-Results.html

Phase-1 for the SARS-CoV-2 protease inhibitor, ALG-097558 has been delayed and is now expected to start in 2023, following a CTA filing in 1Q23. (The prior guidance was for an IND filing in 2H22.)
👍️0
DewDiligence DewDiligence 3 years ago
ALGS—Cash @3/31/22=$183M—$23B burn in 1Q22:

https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500766.html

Other than the financials, there is no new news. ALGS still plans to start phase-1 for its COVID protease inhibitor in late 2022 or early 2023 (i.e. IND filing in 2H22).

No CC.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS selects lead SARS-CoV-2 PI—phase-1 expected to start in early 2023 (or very late 2022):

https://finance.yahoo.com/news/aligos-therapeutics-selects-drug-candidate-120000412.html

The timing of this program was known from the Leerink webcast two months ago (#msg-167924816), so the only new news is that a lead compound has been selected.
👍️0
DewDiligence DewDiligence 3 years ago
ALGS discontinues another HBV candidate:

https://finance.yahoo.com/news/aligos-discontinues-development-antisense-oligonucleotide-120000830.html Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…
👍️0
DewDiligence DewDiligence 3 years ago
ALGS 4Q21 financials—12/31/21_cash=$205.8M:

https://finance.yahoo.com/news/aligos-therapeutics-reports-fourth-quarter-210500703.html

No CC.
👍️0
DewDiligence DewDiligence 3 years ago
Disclosure: I'm long ENTA.
👍️0
DewDiligence DewDiligence 3 years ago
Two takeaways from today's Leerink webcast on ALGS-9711 (oral coronavirus protease inhibitor): 1) ALGS-097111 phase-1 won’t start until 2023 (insofar as the IND is expected to be filed in late 2022); 2) CEO Blatt talked up combination therapy to treat COVID even while insisting compound is “best in class,” which I find curious.
👍️0
DewDiligence DewDiligence 3 years ago
Preclinical data on ALGS-097111 protease inhibitor from 2021 CROI:

https://www.aligos.com/wp-content/uploads/2021/03/CROI21_Science-Spotlight_ID2675_Vandyck_handout_1.pdf
👍️0
DewDiligence DewDiligence 3 years ago
Link to Leerink webcast:

https://wsw.com/webcast/svbleerink67/enta/2640400
👍️0
oxnous oxnous 3 years ago
ALGS--Bungee Jumping

👍️0
DewDiligence DewDiligence 3 years ago
ALGS -40%/PM on_discontinuation_of_lead HBV candidate for_lack_of_efficacy:

https://finance.yahoo.com/news/aligos-halting-further-development-stops-130000126.html
👍️0
DewDiligence DewDiligence 4 years ago
ALGS—(-16%)—sells 5.06M* shares @$19.00—a 20% discount to Monday’s close:

https://finance.yahoo.com/news/aligos-therapeutics-announces-pricing-83-020800387.html

*Assuming exercise of underwriter’s option.
👍️0
DewDiligence DewDiligence 4 years ago
ALGS—(-11%)—presents EASL HBV lineup:

https://finance.yahoo.com/news/aligos-therapeutics-announces-pipeline-upcoming-120000870.html

Nothing in this PR is especially newsworthy, so I’m not sure why the stock is selling off today. Maybe some investors were expecting some kind of big announcement.
👍️0

Your Recent History

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads